ALGS - Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile | Benzinga
The thyroid hormone receptor-beta (THR-b) drug ALG-055009:
- Was well tolerated when oral daily doses up to 1.0 mg were given for 2 weeks in a Phase 1 study in hypercholesterolemic subjects
- Demonstrated favorable PK with low variability
- Dose responsively lowered lipid levels in study subjects
- Was well tolerated in animals following repeated daily dosing in 13 week toxicology studies
- Is more b selective and 5-47x more potent than resmetirom and VK-2809 parent
- Has a favorable overall risk-benefit profile which supports conducting a 12-week Phase 2a study in NASH subjects
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that clinical and nonclinical data for its thyroid hormone receptor-beta (THR-b) drug, ALG-055009, were presented Saturday, November 11th at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, November 10 – 14, 2023. The clinical (#2900-A) and nonclinical (#2461-C) posters for these data can also be found on the "Scientific Presentations & Conferences" section of the Aligos website (www.aligos.com).
The clinical poster describes a Phase 1 study which evaluated 14 oral daily doses of up to 1.0 mg ALG-055009 solution formulation in hypercholesterolemic subjects. Important highlights include:
- ALG-055009 was well tolerated with no safety signals identified
- No clinical evidence of hyper- or hypo-thyroidism was observed
- As expected for a thyromimetic, ALG-055009 dose responsively
- Increased sex hormone binding globulin levels
- Lowered lipids levels
- ALG-055009 exposures increased in a dose proportional manner with ...